SignatureFD
RARE icon

SignatureFD’s Ultragenyx Pharmaceutical RARE Stock Holding History

SignatureFD’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$391 Sell
26
-440
-94% -$10.6K ﹤0.01% 3434
2026
Q2 		$15.6K Buy
466
+232
+99% +$5.76K ﹤0.01% 2456
2026
Q1 		$4.9K Sell
234
-306
-57% -$6.89K ﹤0.01% 2786
2025
Q4 		$12.4K Sell
540
-6
-1% -$197 ﹤0.01% 2327
2025
Q3 		$16.4K Sell
546
-113
-17% -$3.39K ﹤0.01% 2202
2025
Q2 		$24K Buy
659
+80
+14% +$2.88K ﹤0.01% 1972
2025
Q1 		$21K Sell
579
-256
-31% -$10.6K ﹤0.01% 2034
2024
Q4 		$35.1K Sell
835
-40
-5% -$1.98K ﹤0.01% 1758
2024
Q3 		$48.6K Buy
875
+112
+15% +$5.7K ﹤0.01% 1592
2024
Q2 		$31.4K Buy
763
+24
+3% +$1.02K ﹤0.01% 1750
2024
Q1 		$34.5K Buy
739
+62
+9% +$2.92K ﹤0.01% 1737
2023
Q4 		$32.4K Sell
677
-240
-26% -$9.3K ﹤0.01% 1682
2023
Q3 		$32.7K Sell
917
-104
-10% -$4.12K ﹤0.01% 1611
2023
Q2 		$47.1K Buy
1,021
+305
+43% +$14.1K ﹤0.01% 1468
2023
Q1 		$28.7K Sell
716
-746
-51% -$32K ﹤0.01% 1673
2022
Q4 		$67.7K Buy
1,462
+862
+144% +$33.9K ﹤0.01% 1199
2022
Q3 		$25K Buy
600
+361
+151% +$18.6K ﹤0.01% 1639
2022
Q2 		$14K Buy
239
+98
+70% +$6.03K ﹤0.01% 1959
2022
Q1 		$10K Buy
141
+47
+50% +$3.27K ﹤0.01% 2165
2021
Q4 		$8K Buy
94
+67
+248% +$5.45K ﹤0.01% 2229
2021
Q3 		$2K Buy
27
+21
+350% +$1.9K ﹤0.01% 2695
2021
Q2 		$1K Sell
6
-11
-65% -$1.15K ﹤0.01% 2802
2021
Q1 		$2K Sell
17
-5
-23% -$681 ﹤0.01% 2519
2020
Q4 		$3K Buy
22
+16
+267% +$1.9K ﹤0.01% 2165
2020
Q3 		$0 Buy
+6
New +$497 ﹤0.01% 2727
2018
Q4 		– Sell
-1
Closed – – 2042
2018
Q3 		$0 Hold
1
– – ﹤0.01% 1982
2018
Q2 		$0 Hold
1
– – ﹤0.01% 1964
2018
Q1 		$0 Buy
+1
New +$50 ﹤0.01% 1763

Other funds holding RARE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

SignatureFD's RARE Position: Q3 2026 in Review

SignatureFD reduced its Ultragenyx Pharmaceutical (RARE) stake by 94% in Q3 2026, selling an estimated $10.6K and leaving 26 shares worth $391. The position accounts for ﹤0.01% of the portfolio, ranked #3434.

SignatureFD first reported a position in RARE in Q1 2018 and has held it in 28 quarters since. The position peaked at $67.7K in Q4 2022. 84 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • SignatureFD held 26 shares of Ultragenyx Pharmaceutical worth $391 as of Q3 2026.
  • SignatureFD sold 440 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $10.6K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #3434 holding.
  • SignatureFD first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and has held it in 28 quarters since.
  • SignatureFD's Ultragenyx Pharmaceutical position peaked at $67.7K in Q4 2022.
  • 84 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.